Maslimomab

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| verifiedrevid = 458637802

| type = mab

| mab_type =

| source = o

| target = T-cell receptor

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 127757-92-0

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 6A29UE2ZGG

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| chemical_formula =

| molecular_weight =

}}

Maslimomab is a mouse monoclonal antibody{{cite journal |title = Proposed International Nonproprietary Names: Maslimomab |journal = WHO Drug Information |volume = 5 |issue = 4 |date = 1991 |page = 201 |url = http://apps.who.int/medicinedocs/index/assoc/h5791e/h5791e.pdf |location = Geneva |publisher = World Health Organization |archive-url=https://web.archive.org/web/20120223171347/http://apps.who.int/medicinedocs/index/assoc/h5791e/h5791e.pdf |archive-date=23 February 2012 |url-status=dead}} and an immunosuppressive drug.{{cite book | vauthors = Pelletier JP, Mukhtar F | chapter = Passive monoclonal and polyclonal antibody therapies. | veditors = | title = Immunologic Concepts in Transfusion Medicine | date = January 2020 | pages = 251–348 (299) | publisher = Elsevier | location=Philadelphia |isbn=978-0-323-67510-9 | pmc = 7153350 | doi = 10.1016/B978-0-323-67509-3.00016-0 | chapter-url = https://books.google.com/books?id=4PWrDwAAQBAJ&dq=Maslimomab&pg=PA299 }} It is an anti-human T-cell receptor alpha/beta chain.